Pages that link to "Q43629491"
Jump to navigation
Jump to search
The following pages link to Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy v (Q43629491):
Displaying 50 items.
- Preoperative chemotherapy for resectable thoracic esophageal cancer (Q24187910) (← links)
- Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus (Q24796779) (← links)
- Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis (Q24797571) (← links)
- Preoperative therapy in locally advanced esophageal cancer (Q28070310) (← links)
- Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years (Q28081365) (← links)
- Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan (Q30244382) (← links)
- Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS) (Q33387427) (← links)
- Chemotherapy as a component of multimodal therapy for gastric carcinoma (Q33867249) (← links)
- Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. (Q33970074) (← links)
- Neoadjuvant treatment of esophageal cancer (Q34063710) (← links)
- RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma (Q34298027) (← links)
- Perioperative therapy for esophageal cancer (Q34663544) (← links)
- Undervalued criteria in the evaluation of multimodal trials for upper GI cancers (Q34699973) (← links)
- Multimodality management of esophageal cancer (Q34981111) (← links)
- Interobserver reproducibility of diffusion-weighted MRI in monitoring tumor response to neoadjuvant therapy in esophageal cancer (Q35139999) (← links)
- FDG-PET Parameters as Prognostic Factor in Esophageal Cancer Patients: A Review (Q35332601) (← links)
- Palliative therapy for esophageal cancer: laser therapy alone is associated with a better functional outcome. (Q35550190) (← links)
- Esophageal adenocarcinoma and obesity: peritumoral adipose tissue plays a role in lymph node invasion. (Q35793761) (← links)
- Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma (Q35835123) (← links)
- Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression. (Q36057115) (← links)
- Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? (Q36392390) (← links)
- Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer (Q36427789) (← links)
- Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer (Q36609800) (← links)
- The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. (Q36610597) (← links)
- (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. (Q36611842) (← links)
- The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma (Q36613626) (← links)
- Combined-modality therapy for esophageal and gastroesophageal junction cancers (Q36790164) (← links)
- Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? (Q36846116) (← links)
- The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer (Q37076617) (← links)
- Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus (Q37439912) (← links)
- Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma (Q37580437) (← links)
- Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy (Q37612343) (← links)
- Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer (Q37858518) (← links)
- Multimodal treatment for resectable esophageal cancer (Q37900529) (← links)
- Multimodality approach for locally advanced esophageal cancer (Q38060114) (← links)
- Curative treatment of esophageal cancer; an evidenced based review (Q38119170) (← links)
- Neoadjuvant treatment for esophageal squamous cell carcinoma (Q38212234) (← links)
- State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment (Q38340518) (← links)
- Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial (Q38636439) (← links)
- Remnant lymph node metastases after neoadjuvant therapy and surgery in patients with pathologic T0 esophageal carcinoma impact on prognosis: A systematic review and meta-analysis (Q38704657) (← links)
- Novel EGFR-targeted strategy with hybrid peptide against oesophageal squamous cell carcinoma. (Q38787773) (← links)
- Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management (Q38831243) (← links)
- Meta-Analysis for the Therapeutic Effect of Neoadjuvant Therapy in Resectable Esophageal Cancer (Q39053426) (← links)
- Neoadjuvant Treatment for Locally Invasive Esophageal Cancer (Q39167405) (← links)
- Health-related quality of life in patients with oesophageal cancer: analysis at different steps of the treatment pathway (Q39234825) (← links)
- Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis (Q41055901) (← links)
- Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer (Q41202483) (← links)
- Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy (Q41565292) (← links)
- Current management of esophageal squamous-cell carcinoma in Japan and other countries (Q42113341) (← links)
- Clinical and oncological effects of triplet chemotherapy followed by radical esophagectomy for resectable esophageal cancer associated with unfavorable prognostic factors (Q43468195) (← links)